Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Uxin (UXIN) Income towards Parent Company (2017 - 2025)

Uxin filings provide 9 years of Income towards Parent Company readings, the most recent being -$12.5 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 0.72% to -$12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.9 billion, a 55.58% increase, with the full-year FY2025 number at -$39.7 million, up 16.92% from a year prior.
  • Income towards Parent Company hit -$12.5 million in Q4 2025 for Uxin, up from -$8.9 billion in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $23.9 million in Q2 2022 to a low of -$266.1 billion in Q3 2021.
  • Median Income towards Parent Company over the past 5 years was -$10.5 million (2021), compared with a mean of -$16.3 billion.
  • Biggest five-year swings in Income towards Parent Company: soared 322.44% in 2022 and later crashed 12692524.83% in 2023.
  • Uxin's Income towards Parent Company stood at $3.2 million in 2021, then plummeted by 100.44% to -$14178.5 in 2022, then rose by 21.18% to -$11175.0 in 2023, then tumbled by 112696.42% to -$12.6 million in 2024, then rose by 0.72% to -$12.5 million in 2025.
  • The last three reported values for Income towards Parent Company were -$12.5 million (Q4 2025), -$8.9 billion (Q3 2025), and -$10.3 million (Q2 2025) per Business Quant data.